advertisement

BY Taylor Hatmaker

Listen to this ArticleMore info 0:00 / 0:00

The U.S. Food and Drug Administration is adding a new warning label onto GLP-1 drugs like Ozempic and Zepbound for a rare side effect with serious risk.

All GLP-1 drugmakers are now required to include new safety warnings informing patients that the medications could increase their risk of sudden vision loss from a condition known as nonarteritic anterior ischemic optic neuropathy (NAION). The condition, which is not common, can lead to sudden decreased vision in one eye and even permanent vision loss. The condition’s causes aren’t fully understood, but it happens when blood flow to the front of the optic nerve decreases.

“NAION cases have been reported for all currently marketed GLP-1 [receptor agonist] products,” the FDA wrote in its new guidance. The warning will appear on all GLP-1 drugs, including Ozempic, Wegovy, Zepbound, Mounjaro, older GLP-1 agonists, and Foundayo, Eli Lilly’s new GLP-1 pill.…